Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

APEX-AMI - Pexelizumab in Conjunction With Angioplasty

Next Previous
Trial Profile

APEX-AMI - Pexelizumab in Conjunction With Angioplasty

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pexelizumab (Primary)
  • Indications Myocardial infarction
  • Focus Biomarker; Therapeutic Use
  • Acronyms APEX-AMI
  • Sponsors Procter & Gamble

    • Most Recent Events

    • 28 Aug 2023 Results comparing 15-year mortality of ST elevation myocardial infarction of Canadian (STEMI) patients with high-risk electrocardiographic findings enrolled within 6 hours of symptom onset undergoing primary PCI, presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
    • 09 Nov 2019 Results(n=683) of exploratory analysis assessing associations between SR in ST-segment elevation myocardial infarction (STEMI) using a multimarker cardiovascular proteins strategypublished in the American Heart Journal.
    • 13 Feb 2008 Status changed from in progress to completed according to ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top